CD8A and neoplasm: Furthermore, when combined with immunotherapy, POG boosts the anticancer efficacy of the PD-1 inhibitor (clone RMP1–14) in mouse tumor models, intensifies CD8+ T-lymphocyte infiltration in tumors, and demonstrates a novel targeted approach for the PD-1 pathway [105].